Millipore Sigma Vibrant Logo

203811 Bryostatin 1 - CAS 83314-01-6 - Calbiochem

A macrocyclic lactone with antitumor properties.

Bryostatin 1 - CAS 83314-01-6 - Calbiochem: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: Bryo 1, PKC Activator VII, PKC Activator VI

Primary Target: Protein kinase C
View Products on Sigmaaldrich.com
203811
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
83314-01-6C₄₇H₆₈O₁₇

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
203811-10UG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 10 μg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA macrocyclic lactone with antitumor properties. Potently activates protein kinase C and exhibits a high binding affinity (Ki = 1.35 nM). Effectively translocates and down-regulates PKC isozymes α, δ, and ε. Induces a biphasic activation of PKD through a PKC-dependent pathway in intact cells. Also shown to activate Ras in Jurkat T cells and in rat2 cells.
      Catalogue Number203811
      Brand Family Calbiochem®
      SynonymsBryo 1, PKC Activator VII, PKC Activator VI
      References
      ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
      Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
      Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
      Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
      Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
      Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
      Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
      Product Information
      CAS number83314-01-6
      ATP CompetitiveN
      FormWhite to colorless solid or film
      Hill FormulaC₄₇H₆₈O₁₇
      Chemical formulaC₄₇H₆₈O₁₇
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetProtein kinase C
      Primary Target K<sub>i</sub>1.35 nM for protein kinase C
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSEH9455000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      203811-10UG 04055977204025

      Documentation

      Bryostatin 1 - CAS 83314-01-6 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Bryostatin 1 - CAS 83314-01-6 - Calbiochem Analysenzertifikate

      TitelChargennummer
      203811

      Literatur

      Übersicht
      Clamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
      Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
      Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
      Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
      Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
      Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
      Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-December-2018 JSW
      SynonymsBryo 1, PKC Activator VII, PKC Activator VI
      DescriptionA macrocyclic lactone that exhibits anti-tumor properties. Potently activates protein kinase C and exhibits high binding affinity (Ki = 1.35 nM). Effectively translocates protein kinase C (PKC) isozymes α, β, and ε and induces a biphasic, concentration-dependent, down-regulation of PKC δ. Reported to compete with phorbol esters in binding to PKC. Stimulates protein kinase D (PKD) activity in a biphasic, PKC-dependent manner in intact cells. Also activates Ras in Jurkat T cells and in rat2 cells.
      FormWhite to colorless solid or film
      CAS number83314-01-6
      RTECSEH9455000
      Chemical formulaC₄₇H₆₈O₁₇
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (25 mg/ml) or Ethanol (25 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      Merck USA index14, 1457
      ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
      Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
      Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
      Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
      Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
      Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
      Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.